Therapy News and Research

RSS

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

It looks more like an iPod than a medical tool. But the latest miniature ultrasound device created by Cornell biomedical engineering graduate student George K. Lewis could one day introduce a whole new level of home therapy for arthritis, injury and other painful ailments.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

The Ensign Group announces record $542.0M total revenue for full-year 2009

The Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care and assisted living companies, today reported record results for the fourth quarter and full year 2009.

18 Feb 2010

Utah tries to improve state health insurance exhange; Mich. plans for doctor shortage

The Salt Lake Tribune: "State health reform got a boost Tuesday with House passage of a fix-it bill to improve the Utah Health Exchange, an online tool for purchasing health insurance. Pitched as a free-market approach to lowering costs for small businesses, the exchange has had limited success. Only 400 people are receiving health insurance in its experimental first stage. And some of its 66 plans are up to 130 percent more expensive than what some companies were already paying. That's because insurers are calculating premiums differently 'inside' and 'outside' the exchange, said House Speaker Dave Clark" (Stewart, 2/16).

17 Feb 2010

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.

17 Feb 2010

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Pharmasset, Inc. announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.

17 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

IH Systems selects Robotic IV Automation Systems for cytotoxic drug preparation

Following the successful integration of RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - into three healthcare institutions in 2009, and the announcements of several more sales for installation in 2010, medical device company Intelligent Hospital Systems has confirmed the sale of three additional RIVA systems for cytotoxic drug preparation in 2010.

17 Feb 2010

Domino's Pizza raises $2M during 2009 Thanks and Giving campaign for St. Jude Children's Research Hospital

Domino's Pizza, the recognized world leader in pizza delivery, raised $2 million for St. Jude Children's Research Hospital® during the 2009 Thanks and Giving® campaign. This marks the largest single charitable donation in the history of Domino's Pizza.

17 Feb 2010

SBi introduces 10-minute new surgical technique DVD for hand surgeons

Small Bone Innovations, Inc., a leading, privately-held orthopedics company focused exclusively on technologies and treatments for the small bones & joints, is making available to hand surgeons a new 10-minute new surgical technique DVD showing an innovative volar approach to insertion of its SR™ PIP (Proximal Interphalangeal) implant.

17 Feb 2010

UKONS publishes position statement on safe, effective use of oral anticancer medicines

A position statement from the UK Oncology Nursing Society (UKONS) on the safe, effective use of oral anticancer medicines was published online on 5 February 2010 by ecancermedicalscience.

17 Feb 2010

AHF to protest Merck’s Isentress pricing and policies at CROI

AIDS Healthcare Foundation (AHF) will host a protest Wednesday morning, February 17 at 8:00am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, the most expensive first-line AIDS treatment in the US, during the 17th Conference of Retroviruses and Opportunistic Infections (CROI) in San Francisco.

17 Feb 2010

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC). Traditionally, SCLC treatment regimes include chemotherapy and radiotherapy for limited stage disease; however, the study concludes that in selected patients with early stage disease a lobectomy (removal of lung) had an excellent overall survival without additional treatment.

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Disparities in breast cancer treatment: African-American women diagnosed in later stages of disease

Cancer, the peer-reviewed international journal of the American Cancer Society, has published a study conducted by HealthCore, Inc. in its Jan. 1 edition, demonstrating disparities in breast cancer treatment between commercially insured African-American and white women.

17 Feb 2010

Low RVEF increases risk of death in patients with systolic heart failure

New research from the University of Alabama at Birmingham (UAB) suggests that the ability of right side of the heart to pump blood may be an indication of the risk of death to heart-failure patients whose condition is caused by low function by the left side of their heart.

17 Feb 2010

UWM engineer creates software program that foresees outcome before stem cell divides

A software program created by an engineer at the University of Wisconsin-Milwaukee (UWM) can not only predict the types of specialized cells a stem cell will produce, but also foresee the outcome before the stem cell even divides.

17 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

Therapy News and Research

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

Genzyme announces fourth-quarter and full-year 2009 financial results

The Ensign Group announces record $542.0M total revenue for full-year 2009

Utah tries to improve state health insurance exhange; Mich. plans for doctor shortage

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

IH Systems selects Robotic IV Automation Systems for cytotoxic drug preparation

Domino's Pizza raises $2M during 2009 Thanks and Giving campaign for St. Jude Children's Research Hospital

SBi introduces 10-minute new surgical technique DVD for hand surgeons

UKONS publishes position statement on safe, effective use of oral anticancer medicines

AHF to protest Merck’s Isentress pricing and policies at CROI

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Disparities in breast cancer treatment: African-American women diagnosed in later stages of disease

Low RVEF increases risk of death in patients with systolic heart failure

UWM engineer creates software program that foresees outcome before stem cell divides

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News